Generic Drug Service, Not Pricing, Is Key Performance Factor – Lehman’s Silver
Executive Summary
The success of generic companies will be determined more by the breadth and quality of their offerings than product pricing, Lehman Brothers Senior VP-Specialty Pharmaceutical Research Rich Silver told the Generic Pharmaceutical Association
You may also be interested in...
Barr Seeks To Capitalize On Pliva Infrastructure, Faces Obstacles To Benefits
Barr is moving ahead with its integration of Pliva, but the firm must overcome several obstacles before it can capitalize on its recently acquired European infrastructure
Teva Retains Simvastatin Share As New Entrants Struggle To Meet Demand
Generic companies may find it difficult to assess how much supply to produce when a large product loses 180-day exclusivity, comments by Teva Pharmaceuticals USA CEO William Marth suggest
Generic Firms Sanguine About New Congress, Preparing For Biogeneric Action
Among a number of potential congressional actions that could benefit the generic industry, generic manufacturers appear to be most bullish about the prospects for the establishment of a pathway for follow-on biologics